University of Texas MD Anderson Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2022

  1. The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations

    JCO global oncology, Vol. 8, pp. e2200123

2020

  1. Precision prevention and cancer interception: The new challenges of liquid biopsy

    Cancer Discovery, Vol. 10, Núm. 11, pp. 1635-1644

2019

  1. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging

    Thorax, Vol. 74, Núm. 4, pp. 371-379

  2. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

  3. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2015

  1. Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546]

    Biochimica et Biophysica Acta - Reviews on Cancer

2014

  1. Liquid biopsies in lung cancer: The new ambrosia of researchers

    Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1846, Núm. 2, pp. 539-546

  2. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

    Cancer Treatment Reviews, Vol. 40, Núm. 8, pp. 990-1004

2011

  1. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance

    Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166